News Sanofi makes Alzheimer's play with Vigil takeover Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience.
News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
News BioMarin starts rebuilding after its downsizing spree BioMarin has made its first M&A play under James Sabry, buying Inozyme to flesh out its enzyme replacement therapies (ERTs) for rare diseases.
News Datavant, Aetion merger creates real-world data force Datavant and Aetion merger promises "faster, more actionable" real-world data insights across pharma's clinical and commercial lifecycle.
News GSK pays $1.2bn for liver drug as it culls TIGIT programme GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.
News Shionogi aims to buy tobacco giant's pharma unit for $1bn Shionogi has reached a $1.04bn agreement to buy Torii, the pharma subsidiary of Japan Tobacco, as it tries to meet an ambitious sales target.
News ASCO 25: Roche places Itovebi marker in breast cancer Roche's Itovebi has become the first PI3K inhibitor to extend survival in HR-positive, HER2-negative breast cancer with a PIK3CA mutation.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
